Showing results (41-50 of 66) with videos related to

Sort By:
Pageof 7
Scientific Reports|October 22, 2020
Pharmacologic profiling of patient-derived xenograft models of primary treatment-naïve triple-negative breast cancerReid T Powell, Abena Redwood, Xuan Liu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 26, 2015
Hypoxia-Activated Prodrug TH-302 Targets Hypoxic Bone Marrow Niches in Preclinical Leukemia ModelsJuliana Benito, Marc S Ramirez, Niki Zacharias Millward, et al.
Nature Communications|April 17, 2023
Ether phospholipids are required for mitochondrial reactive oxygen species homeostasisZiheng Chen, I-Lin Ho, Melinda Soeung, et al.
Biorxiv : the Preprint Server for Biology|February 7, 2023
Combined KRAS<sup>G12C</sup> and SOS1 inhibition enhances and extends the anti-tumor response in KRAS<sup>G12C</sup>-driven cancers by addressing intrinsic and acquired resistanceVenu Thatikonda, Hengyu Lu, Sabine Jurado, et al.
Journal of Medicinal Chemistry|October 13, 2021
Discovery of 6-[(3<i>S</i>,4<i>S</i>)-4-Amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-3-(2,3-dichlorophenyl)-2-methyl-3,4-dihydropyrimidin-4-one (IACS-15414), a Potent and Orally Bioavailable SHP2 InhibitorBarbara Czako, Yuting Sun, Timothy McAfoos, et al.
Cancer Research|September 14, 2021
Oxidative Phosphorylation Is a Metabolic Vulnerability in Chemotherapy-Resistant Triple-Negative Breast CancerKurt W Evans, Erkan Yuca, Stephen S Scott, et al.
Science Translational Medicine|April 19, 2019
Resistance to neoadjuvant chemotherapy in triple-negative breast cancer mediated by a reversible drug-tolerant stateGloria V Echeverria, Zhongqi Ge, Sahil Seth, et al.
Journal of Medicinal Chemistry|August 14, 2020
Discovery of IACS-9439, a Potent, Exquisitely Selective, and Orally Bioavailable Inhibitor of CSF1RBarbara Czako, Joseph R Marszalek, Jason P Burke, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 14, 2021
Phase Ib Dose Expansion and Translational Analyses of Olaparib in Combination with Capivasertib in Recurrent Endometrial, Triple-Negative Breast, and Ovarian CancerShannon N Westin, Marilyne Labrie, Jennifer K Litton, et al.
Mabs|December 9, 2024
A TRAILR2/CDH3 bispecific antibody demonstrates selective apoptosis and tumor regression in CDH3-positive pancreatic cancerPeter Jung, Stefan P Glaser, Jing Han, et al.
Pageof 7